RESUMEN
Background: The exact nature of the association between metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS) is still not completely understood. There appears to be support for the hypothesis that metabolic and pathological derangements characterizing MetS can promote the development and progression of Benign Prostatic Enlargement and LUTS. Methods: A total of 212 patients were included in the study, of whom 106 (50%) had LUTS and metabolic syndrome and 106 (50%) had LUTS without metabolic syndrome. The severity of the patient抯 lower urinary tract symptoms was assessed by the International Prostate Symptom Score (IPSS). Erectile function was assessed by a 5 question International Index of Erectile Function (IIEF) Questionnaire. MetS was defined according to the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII). Results: The study showed a statistically significant association between prostate volume, IPSS score, and each individual component of metabolic syndrome. There is a significant association between metabolic syndrome and sexual dysfunction in men, and the severity of lower urinary tract symptoms is correlated with the severity of erectile dysfunction in the age group in the department of urology. Conclusions: Patients with MetS, characterized by increased waist circumference, BMI, triglycerides, and decreased HDL levels, exhibited more severe Lower urinary tract symptoms, along with heightened sexual dysfunction, particularly erectile and ejaculatory dysfunction.
RESUMEN
【Objective】 To explore the correlation between body mass index (BMI) and lipid indexes with prostate volume in patients with benign prostatic hyperplasia (BPH) so as to provide reference for the clinical prevention of this disease. 【Methods】 Clinical data of 578 patients admitted to the Department of Urology of Chinese PLA General Hospital during Jan.2014 and Dec.2022 were collected.The patients underwent initial prostate puncture biopsy or prostatectomy and BPH was confirmed pathologically.The patients’ age, time of onset of the disease, BMI, past medical history and biochemical indexes were analyzed.According to the total prostate volume (TPV) grading, the patients were divided into TPV>75 mL and TPV≤75 mL groups.The general data of the two groups were compared, and predictors of TPV were determined with linear regression analysis.The samples were stratified with BMI to observe the differences in the effects of apolipoprotein B (ApoB) on TPV. 【Results】 There were 215 cases in the TPV>75 mL group and 363 cases in the TPV≤75 mL group.The levels of BMI, triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (ApoB) were higher in the TPV>75 mL group (P0.05), and ApoB predicted prostate volume growth in overweight and obese BPH population respectively (β=26.411, P=0.011; β=47.602, P=0.017). 【Conclusion】 Age, ApoB and BMI can be used as predictors of volume growth in BPH patients, which can help further research on the pathogenesis and progression of BPH.
RESUMEN
Background: Benign prostatic hyperplasia (BPH) is clinically defined as prostate adenoma, resulting in bladder outlet obstruction (BOO), which may eventually harm the bladder and even kidneys. For differential diagnosis of male LUTS, uroflowmetry can be used together with non-invasive ultrasound to ascertain the flow rate and IPP. PSA is also an important indicator for differential diagnosis. International prostate symptoms score (IPSS) is used to assess the severity of the symptoms for clinical BPH. There is also a recommendation to consider the quality of life (QoL) index, where a QoL score of ?3 is considered as worrisome. Methods: This was a retro-prospective study based on secondary and primary data collection and analysis, pertaining to BPH patients who visited the study site previously as well as those who are coming for regular follow-up since 2019. Patient enrolment was done at a teaching hospital Shree Krishna Hospital affiliated to the Pramukh Swami Medical College, Bhaikaka University, Karamsad. About 100 patients presenting with lower urinary tract symptoms (LUTS) and histo-pathologically proven cases of BPH were enrolled to pursue research objectives. All patients were followed up to a period of 3-months after initiating the treatment and disease severity through IPSS and quality of life upon completion of treatment were also assessed. Results: PSA is also an important indicator for differential diagnosis, which is generally less than 1 ?g/l in patients in absence of clinically confirmed BPH. In our study, mean prostate volume was reported to be 43.46±19.35 cc. A positive correlation was observed between prostate volume and serum PSA with disease severity. Conclusions: Our study evaluated the IPSS to predict the disease severity and correlated it with quality of life, prostate volume and serum PSA. Our findings were in line with currently available evidences, and suggested that QoL, prostate volume and serum PSA are better predictors of disease severity, IPSS.
RESUMEN
【Objective】 To establish a model for predicting the risk of urinary incontinence after holmium laser enucleation of the prostate (HoLEP). 【Methods】 The clinical data of 258 patients with benign prostatic hyperplasia (BPH) who underwent HoLEP in our hospital during Jan.2019 and Feb.2022 were retrospectively analyzed. According to the occurrence of urinary incontinence after surgery, they were divided into the urinary incontinence group (n=84) and non-urinary incontinence group (n=174). Lasso regression was used to screen the predictors of urinary incontinence after HoLEP. Logistic regression was used to establish a suitable model, and a nomogram of urinary incontinence after HoLEP was drawn. Bootstrap was used to verify and draw the calibration curve of the model, calculate the C index, and draw the clinical decision curve to further verify the accuracy and identification ability of the model. 【Results】 Predictors including International Prostate Symptom Score (IPSS), Quality of Life Score (QoL), body mass index (BMI), diabetes, prostate volume (PV), and prostate-specific antigen (PSA) were selected, based on which a prediction model was constructed. The area under the receiver operating characteristic (ROC) curve of the prediction model was 0.766 0, and the 95% confidence interval was 0.704-0.828. Bootstrap internal validation showed a C-index of 0.766 2, and the calibration model curve coincided well with the actual model curve. The clinical decision curve analysis showed that the model had high accuracy, and net benefit in the probability of urinary incontinence was within 10% to 82%. 【Conclusion】 IPSS, QoL, diabetes, prostate volume, and PSA are predictors that can affect the occurrence of urinary incontinence after HoLEP. The model has high accuracy, identification ability and net benefit.
RESUMEN
A cross-sectional study was conducted to estimate the age-stratified normal levels and age-related changes in the risk predictors of benign prostatic hyperplasia (BPH) progression. A total of 4706 male participants aged 40 years or older in Zhengzhou (China) were enrolled. The values of the International Prostate Symptom Score (IPSS), prostate-specific antigen (PSA), prostate volume (PV), and postvoid residual urine volume (PVR) significantly increased with age. Nonlinear relationships between age and IPSS scores ≥8 (P for nonlinearity = 0.046), PSA level ≥1.6 ng ml-1, PV ≥31 ml, or PVR ≥39 ml (all P for nonlinearity <0.001) were observed. After the age of 61 years, the risk indicators related to BPH progression were positively correlated with age (odds ratio [OR] >1), regardless of the predictors of the IPSS score, PSA level, PV, or PVR; and the OR values increased gradually. Therefore, after the age of 61 years, the risk predictors related to BPH progression were positively correlated with age.
Asunto(s)
Humanos , Masculino , Hiperplasia Prostática/diagnóstico , Antígeno Prostático Específico , Estudios Transversales , Pueblos del Este de Asia , Factores de RiesgoRESUMEN
Objective To explore the diagnostic value of combined clinical factors for transitional zone clinically significant prostate cancer(csPCa)in the lesion with category 3 or 4 of prostate imaging reporting and data system version 2.1(PI-RADS v2.1).Methods The data of 251 patients of pathologically confirmed transitional zone lesions were analyzed retrospectively,the age,prostate specific antigen(PSA),prostate volume(PV)and the related derived indicators in patients with csPCa and non-csPCa were analyzed.To determine independent predictors for the diagnosis of csPCa.Receiver operating characteristic(ROC)curve was used to assess the diagnostic efficacy when each factor was applied individually and in combination,and the optimal diagnostic threshold was also calculated.Results There were 188 cases in the non-csPCa group and 63 cases in the csPCa group in 251 patients.Univariate and multivariate logistic regression analysis showed prostate specific antigen density(PSAD)[odds ratio(OR)=3.745]and PV(OR=0.98)were independent predictors of csPCa(P＜0.05),and the optimal diagnostic threshold was:PSAD＞0.22 ng/(mL·cm3),PV≤46.95 cm3,the combined diagnostic performance was higher than that of PI-RADS v2.1 and PV alone[area under the curve(AUC):0.791,0.661,0.703],but comparable to that of PSAD alone,the difference was no statistically significant(Z=1.423,P=0.154 8).Conclusion Combined clinical factors can improve the diagnostic performance for csPCa in the transitional zone in the lesion with category 3 or 4 of PI-RADS v2.l,the value of PSAD and PV should be paid attention to.
RESUMEN
To evaluate whether prostate volume (PV) would provide additional predictive utility to the prostate health index (phi) for predicting prostate cancer (PCa) or clinically significant prostate cancer, we designed a prospective, observational multicenter study in two prostate biopsy cohorts. Cohort 1 included 595 patients from three medical centers from 2012 to 2013, and Cohort 2 included 1025 patients from four medical centers from 2013 to 2014. Area under the receiver operating characteristic curves (AUC) and logistic regression models were used to evaluate the predictive performance of PV-based derivatives and models. Linear regression analysis showed that both total prostate-specific antigen (tPSA) and free PSA (fPSA) were significantly correlated with PV (all P 0.05). In conclusion, PV-based derivatives (both PHIV and PHID) and models incorporating PV did not improve the predictive abilities of phi for either PCa or clinically significant PCa.
RESUMEN
Lower Urinary tract symptom (LUTS) is a common presentation among elderly male patients in urology clinical practice. International Prostate Symptom Score (IPSS) have contributed much to the objective and quantitative evaluations of LUTS in terms of the elucidation of its pathogenesis and changes accompanied with treatments. Aim: The objective of this study was to evaluate the relationship between IPSS and prostate volume in patients with LUTS. Methods: This prospective study included 58 male patients with lower urinary tract symptoms (LUTS). The IPSS was evaluated using questionnaire and the prostate volume of each patient was then estimated by transabdominal ultrasound. Results: There is a significant relationship between IPSS and prostate volume measured through trans-abdominal ultrasonography. The Total IPSS increases with the prostate volume, as a significant positive relationship between IPSS total score and prostate volume was recorded. Conclusion: There is a significant positive relationship between IPSS total score and prostate volume
RESUMEN
Background: Benign prostatic hyperplasia is closely related with ageing. The present study was conducted to assess the ability of transabdominal ultrasonography in diagnosing benign and/or malignant hypertrophy of the prostate.Methods: An observational study was done in the Department of Radiology, Bharati Vidyapeeth Medical College and Hospital (Deemed to be University), Sangli, Maharashtra, India of patients who had prostatomegaly on transabdominal ultrasound examination and underwent histopathological confirmation of the lesions from 1 October 2018 till 31 December 2018. The prostate gland was assessed for volume, echotexture, morphology, focal lesions and median lobe.Results: Out of 155 patient’s benign prostatic disease was diagnosed in 116 patients, while malignancy was detected in the rest of the 39 cases. Prostate specific antigen levels were significantly higher among malignant cases (18.39±7.44 ng/ml) as compared to that of benign cases (7.51±3.22 ng/ml), p value <0.01. Benign lesions were predominantly inner glandular, while malignant cases were mainly peripheral. Moderate vascularity was found in 76.9% of the malignant cases. Focal vascular asymmetry was found in 74.4% of the malignant cases and only 12% of the benign cases. Sensitivity of transabdominal ultrasonography in diagnosing malignant prostatic lesions was 94.8%, specificity was 75% with an overall accuracy of using transabdominal ultrasonography in the diagnosis of malignant prostatic lesions in this study population was 80%.Conclusions: Transabdominal ultrasound evaluation of prostate is a simple, economical, non-invasive technique of choice due to its high accuracy in detecting size, nature of pathology as benign or malignant with fair accuracy.
RESUMEN
Background: Patients with high prostate volume (>80 ml) and high PSA levels make it difficult to decide on prostate biopsy. In this study, author aimed to detect of predictive factors to distinguish malignant or benign prostatic lesions in patients with prostate size over 80 ml.Methods: A total of 299 patients underwent TRUSBP at the clinics between 2012-2017. Cases with prostate volume over 80 ml were divided into groups according to the pathology by benign (group 1) or malign (group 2). Author evaluated the predictive factors in two groups. Patient’s age, grading and findings of digital rectal examination, prostate volume, number of received cores, total (tPSA) and free PSA (fPSA) before biopsy, rate of percentage of free to total prostate specific antigen (f/tPSA) and PSA density was compared in both groups.Results: Benign prostate hyperplasia was detected in 217 patients (72.58%) and prostate adenocarcinoma was detected in 82 patients (27.42%). The patient’s age, tPSA, fPSA and PSA density were 63.81 years, 9.71 ng/ml, 1.78 ng/ml and 0.10 g/ml2 in group 1 and 69.10 years, 38.32 ng/ml, 5.86 ng/ml and 0.42 ng/ml2 respectively. Patient’s age, tPSA, fPSA and PSA density was statistically significant between in two groups (p<0,05). Number of received cores and rate of f/tPSA were 14.02-13.84% and 19.06-17.62% in group 1 and 2, respectively and was not statistically significant. In group 2, prostate adenocarcinoma was most common detected with Gleason score 4+3 in 21 of 82 patients (25.6%).Conclusions: High prostate volume (>80 ml) has a significant influence in PSA values and results of the biopsy, PSA density is extremely important in performing prostate biopsy decisions.
RESUMEN
We evaluated whether the prostate-specific antigen (PSA) mass or free PSA (fPSA) mass (i.e., absolute amount of total circulating PSA or fPSA protein, respectively), versus serum PSA or fPSA concentration, improves the accuracy of predicting the total prostate volume (TPV) in relation to obesity. Among men whose multicore (≥12) transrectal prostate biopsy was negative, 586 who had a PSA of ≤10 ng ml-1 and underwent the fPSA test prior to biopsy were enrolled. The PSA mass or fPSA mass (μ g) was calculated by multiplying the serum level by plasma volume. At each TPV cut-off point (30 ml, 40 ml, and 50 ml), the areas under the receiver operating characteristics curve (AUCs) of each variable were compared in obesity-based subgroups. AUCs of fPSA and fPSA mass for predicting TPV were significantly larger than those for PSA and PSA mass by 8.7%-12.1% at all cut-off points. Subgroup analyses based on obesity showed that, although PSA mass and fPSA mass enhanced accuracy by 4% (P = 0.031) and 1.8% (P = 0.003), respectively, for determining TPVs of ≥30 ml and ≥50 ml in obese and overweight men, they did not improve the accuracy in most other combinations of the degrees of obesity with TPV cut-off points. Thus, compared with serum PSA or fPSA, the absolute amount of PSA or fPSA protein mass improved the accuracy of predicting TPV in obese men very minimally and only for certain TPV cut-off points. Hence, these indicators may not provide clinically meaningful improvement in predicting TPV in obese men.
RESUMEN
Objective@#To assess the clinical effects of transurethral holmium laser enucleation of the prostate (HoLEP) combined with Jisheng Shenqi Decoction (HoLEP + JSSD) on BPH.@*METHODS@#This study included 110 BPH patients treated in our hospital from August 2017 to April 2018, who were randomly assigned to receive HoLEP (n = 55) or HoLEP + JSSD (n = 55). We compared the pre- and post-operative IPSS, quality of life (QOL) score, prostate volume, postvoid residual urine volume (PVR), maximum urinary flow rate (Qmax), average urinary flow rate (Qavg) and levels of serum T, E2 and T/E2 as well as postoperative complications between the two groups of patients.@*RESULTS@#After treatment, both IPSS and QOL score were significantly lower in the HoLEP + JSSD than in the HoLEP group (P 0.05) or the total incidence rate of complications postoperatively (21.82% vs 29.09%, P > 0.05).@*CONCLUSIONS@#HoLEP + JSSD can significantly alleviate the lower urinary tract symptoms as well as improve the QOL and bladder and urinary tract functions of BPH patients.
RESUMEN
<p><b>Objective</b>To evaluate the analgesic effect of intrarectal local anesthesia (IRLA) versus that of periprostatic nerve block anesthesia (PPNB) in initial transrectal ultrasound-guided prostate biopsy (TRUS-PB) for patients with different prostate volumes (PV).</p><p><b>METHODS</b>A total of 253 patients undergoing initial TRUS-PB in our hospital from January 2014 to November 2017 were divided into three PV groups (<50 ml, 50－100 ml, and >100 ml), each again randomized into three subgroups (control, IRLA, and PPNB) with the random number table method. The pain during the procedure was assessed based on the Visual Analogue Scale (VAS) scores and the blind method was used by the biopsy operator, VAS valuator and data analyst.</p><p><b>RESULTS</b>Among the patients with PV <50 ml, the VAS scores in the blank control, IRLA, and PPNB subgroups were 4.39±0.87, 3.51±0.84 and 3.43±1.07, respectively, remarkably higher in the control than in the IRLA and PPNB groups (P<0.05), but with no statistically significant differences between the latter two (P>0.05). Among those with PV of 50－100 ml, the VAS scores in the three subgroups were 4.50±1.05, 4.38±1.13 and 3.38±1.44, respectively, markedly higher in the control and IRLA than in the PPNB group (P<0.05), but with no statistically significant differences between the former two groups (P>0.05). Among those with PV >100 ml, the VAS scores in the three subgroups were 5.19±1.05, 5.00±1.25 and 4.19±0.91, respectively, remarkably higher in the former two groups than in the latter (P<0.05), but with no statistically significant differences between the former two groups (P>0.05).</p><p><b>CONCLUSIONS</b>Either IRLA or PPNB can be recommended for initial TRUS-PB in patients with PV <50 ml, PPNB for those with PV of 50－100 ml, and PPNB with other painkillers for those with PV >100 ml.</p>
Asunto(s)
Anciano , Humanos , Masculino , Administración Rectal , Anestesia Local , Métodos , Anestésicos Locales , Biopsia , Bloqueo Nervioso , Métodos , Dimensión del Dolor , Dolor Asociado a Procedimientos Médicos , Estudios Prospectivos , Próstata , PatologíaRESUMEN
We evaluated whether the prostate-specific antigen (PSA) mass or free PSA (fPSA) mass (i.e., absolute amount of total circulating PSA or fPSA protein, respectively), versus serum PSA or fPSA concentration, improves the accuracy of predicting the total prostate volume (TPV) in relation to obesity. Among men whose multicore (≥12) transrectal prostate biopsy was negative, 586 who had a PSA of ≤10 ng ml-1 and underwent the fPSA test prior to biopsy were enrolled. The PSA mass or fPSA mass (μ g) was calculated by multiplying the serum level by plasma volume. At each TPV cut-off point (30 ml, 40 ml, and 50 ml), the areas under the receiver operating characteristics curve (AUCs) of each variable were compared in obesity-based subgroups. AUCs of fPSA and fPSA mass for predicting TPV were significantly larger than those for PSA and PSA mass by 8.7%-12.1% at all cut-off points. Subgroup analyses based on obesity showed that, although PSA mass and fPSA mass enhanced accuracy by 4% (P = 0.031) and 1.8% (P = 0.003), respectively, for determining TPVs of ≥30 ml and ≥50 ml in obese and overweight men, they did not improve the accuracy in most other combinations of the degrees of obesity with TPV cut-off points. Thus, compared with serum PSA or fPSA, the absolute amount of PSA or fPSA protein mass improved the accuracy of predicting TPV in obese men very minimally and only for certain TPV cut-off points. Hence, these indicators may not provide clinically meaningful improvement in predicting TPV in obese men.
RESUMEN
Previous investigations have shown that changes in total prostate volume (TPV) are highly variable among aging men, and a considerable proportion of aging men have a stable or decreasing prostate size. Although there is an abundance of literature describing prostatic enlargement in association with benign prostatic hyperplasia, less is known about the appropriate age cut-off points for TPV growth rate. In this community-based cohort study, TPV was examined once a year in men who had consecutive health checkup, during a follow-up of 4 years. A total of 5058 men (age 18-92 years old) were included. We applied multiple regression analyses to estimate the correlation between TPV growth rate and age. Overall, 3232 (63.9%) men had prostate growth, and 1826 (36.1%) had a stable or decreased TPV during the study period. The TPV growth rate was correlated negatively with baseline TPV (r=-0.32, P<0.001). Among 2620 men with baseline TPV <15 cm, the TPV growth rate increased with age (β=0.98, 95% CI: 0.77%-1.18%) only up to 53 years old. Among 2188 men with baseline TPV of 15-33.6 cm, the TPV growth rate increased with age (β=0.84, 95% CI, 0.66%-1.01%) only up to 61 years old after adjusting for factors of hypertension, obesity, baseline TPV, diabetes mellitus and dyslipidemia. In this longitudinal study, the TPV growth rate increased negatively with baseline TPV, only extending to a certain age and not beyond. Further research is needed to identify the mechanism underlying such differences in prostate growth.
Asunto(s)
Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Masculino , Persona de Mediana Edad , China , Hipertensión , Epidemiología , Obesidad , Epidemiología , Tamaño de los Órganos , Próstata , Patología , Hiperplasia Prostática , Epidemiología , Características de la ResidenciaRESUMEN
Benign prostatic hyperplasia (BPH) is the non-malignant enlargement of the prostate. Estimation of Prostate volume and dimensions contribute significantly to the management of BPH. Correlations between the trans-abdominal and trans-rectal ultrasound methods in estimating prostate volume and dimensions were studied with variable results. Ninety-one consecutive patients of 50 years or older with were scanned by Trans abdominal and transrectal sonographs (TA&TRUS) at the same session after obtaining the consent. All the scans were performed on a single ultrasound machine. The volume and dimensions of the prostate obtained by both methods were compared and correlated using Pearson correlation coefficient. The data was analysed further in groups based on volumes and ethnicity. Twenty-four patients were also scanned by other consultant radiologist and the data was analysed to compare the interobserver variations. Results: The mean age of the patients was 66.03±10.41 years. The mean prostate volume for ninety one patients by TA & TRUS was 44.4±35.1 ml and 46.2±34.7 ml, respectively (r = 0.965, p<0.001). Among the total patients 42 were of East Indian (EI) origin, 45 were of Caribbean African (CA) origin and 4 were of mixed race. The mean prostate volume of EI race by TA & TRUS was 35.3±23.3 and 38.9±25.9 ml respectively(r = 0.950, p<0.001). The mean prostate volume of CA race by TA & TRUS was 50.8±39.4 and 51.0±38.5 ml, respectively (r = 0.967, p<0.001). The mean prostate volume of observer A and observer B by TA & TRUS was 43.5±28.8 and 45.8±25.9 ml (r = 0.953, P<0.001) and 46.6±39 and 46.9±27.4 ml (r = 0.877, p<0.001) respectively. Conclusion: Strong correlation between TA & TRUS estimation of prostate volume and dimensions for volumes up to 100ml found in our study offers TAUS as a cost effective, less invasive, quick and well tolerable alternative to TRUS. TRUS however may be a reasonable choice for accurate measurements in larger (>100 millilitres) prostates, this needs to be further investigated by a larger sample size.
RESUMEN
Objectives: To establish the local reference range of prostate volume according to our subset of population. To correlate prostate volume (PV) with age, body mass index (BMI) and waist circumference (WC). Methods: A cross-sectional study with 119 healthy adults aged 40-79 years without any prostatic pathology were recruited .The study population was categorized into 4 age groups (40 - <50 yrs, 50 -<60 yrs, 60-<70 yrs, 70-<80 yrs), 3 BMI groups (healthy, obese and overweight) and 2 WC groups (<90 cm and >90 cm). A p-value of <0.05 was considered significant. Results: The mean prostate volume was 21.7±2.2 mls, mean body mass index was 28±6 kg/m², whereas mean waist circumference was 95 cm. PV was found to be higher in obese and >90 cm waist circumference group. After applying multiple regression analysis, waist circumference correlated positively and significantly with prostate volume. Conclusion: Mean prostate volume in our studied population was smaller than that of many western populations. Our study has proved that central obesity is the most important factor influencing prostate volume.
RESUMEN
PURPOSE: The goal of this study is to investigate the effects of androgen deprivation therapy (ADT) on total prostate volume and lower urinary tract symptoms (LUTS). METHODS: Between January 2007 and June 2014, 110 patients who received androgen deprivation treatment were enrolled in this retrospective study. Clinical parameters and urodynamic parameters along with changes at follow-up were analyzed. Factors such as reduction in prostate volume, changes in LUTS, and prostate volume tertiles were compared 1 year after ADT. RESULTS: After ADT, the total International Prostate Symptom Score (IPSS) score decreased from 17.45 to 12.21 and the IPSS voiding subscore decreased from 9.16 to 6.24. Maximal uroflow rate increased from 8.62 to 11.50 mL/sec and residual urine also reduced significantly by 29.34 mL. Change in prostate size was more prominent (–51.14%) in the patients with less than 1 year of ADT (n=21) than those who had more than 1 year of treatment (n=89, –44.12%). The decrease in the IPSS voiding subscore was greater within 1 year of ADT than after 1 year of treatment (–4.10 vs. –2.65). The differences were more significant in the 30–50 g group (n=59) and >50 g group (n=11) than the <30 g group (n=40) of the IPSS voiding subscore improvement (–3.76 , –4.91 vs. –2.10), and maximal uroflow rate improvement (2.78, 2.90 vs 1.49). CONCLUSION: ADT resulted in statistically significant clinical improvement in terms of prostate volume, urodynamic parameters, and LUTS for patients with prostate cancer when analyzed by ADT duration and prostate volume.
Asunto(s)
Humanos , Estudios de Seguimiento , Corea (Geográfico) , Síntomas del Sistema Urinario Inferior , Próstata , Neoplasias de la Próstata , Estudios Retrospectivos , UrodinámicaRESUMEN
Background: Benign prostatic hyperplasia (BPH) is a common disease in old age individuals, usually starts around the age of 40 years, the prevalence of benign prostatic hyperplasia rises to more than 50% at 50 years of age to as much as 90% at the age of 85 years. Proven BPH patients suffer from moderate to severe lower urinary tract symptoms (LUTS) that are symptoms related to storage and voiding of urine. This study was to determine relationship between sonologically measured prostate Volume and international prostate symptom score (IPSS). Methods: Clinically symptomatic 126 patients in the age group of 40-89 years were studied. All the patients underwent Transabdominal sonography for the estimation of prostate volume and clinical questionnaire for international prostate symptom score. Statistical Analysis by descriptive and analytical statistics using SPSS version 16. Chi-Square test used and P values ≤ 0.05 was considered to be statistically significant. Results: Among 126 individuals, The maximum number of patients, that is 45 patients had the prostate volume measuring 31-50 cc (35.7%), followed by 25 patients (19.8%) had the volume measuring more than 50 cc. Maximum number of patients 52 (41.3%) were having severe symptoms, 47 (37.3%) patients were having moderate symptoms and 27 patients symptoms and 27 patients (21.4%) were having mild symptoms. Prostate volume had statistically significant but weak correlation observed with IPSS (r=0.40, p=0.001), Weak Stream (r=0.31, p=0.001) and urgency (r=0.31, p=0.001). Conclusions: Prostate volume had statistically significant but weak correlation observed with IPSS.
RESUMEN
BACKGROUND: Benign prostatic hyperplasia (BPH) is a common condition in males over 40 years old, and the incidence of BPH has a tendency to increase with age. Obesity is state of excessive accumulation of fat in the body that leads to changes in the body's metabolism and endocrine function. Therefore, progression of BPH occurs in the obese state according to many articles. The purpose of this study was to compare the efficacy of obesity indices which correlate with prostate volume. METHODS: The study was carried out in 285 males, who visited a health promotion center and underwent transrectal ultrasonography and abdominal fat computed tomography from April, 2010 to June, 2013. Anthropometric parameters were measured directly and blood samples were obtained in the morning after over eight hours of fasting. The correlation between obesity indices and prostate volume was analyzed. RESULTS: After adjusting for age, prostate volume was positively correlated with BMI (r=0.227, P<0.001), waist circumference (WC) (r=0.151, P=0.011), waist to height ratio (WHtR) (r=0.149, P=0.012), and visceral fat area (VFA) (r=0.157, P=0.008). However prostate volume showed no correlation with subcutaneous fat area (SFA) and visceral to subcutaneous ratio (VSR). WHtR had the largest area under the curve (AUC) for the identification of prostate volume more than 30 mL (AUC=0.595, P=0.017) followed by VFA and BMI in order. CONCLUSION: Prostate volume was positively correlated with BMI, WC, WHtR, and VFA among the obesity indices and WHtR had the largest AUC followed by VFA and BMI in order.